U.S. Markets close in 5 hrs 28 mins
  • S&P 500

    3,415.13
    -50.26 (-1.45%)
     
  • Dow 30

    27,797.83
    -537.74 (-1.90%)
     
  • Nasdaq

    11,459.34
    -88.95 (-0.77%)
     
  • Russell 2000

    1,617.59
    -22.91 (-1.40%)
     
  • Crude Oil

    38.71
    -1.14 (-2.86%)
     
  • Gold

    1,907.90
    +2.70 (+0.14%)
     
  • Silver

    24.56
    -0.11 (-0.47%)
     
  • EUR/USD

    1.1816
    -0.0052 (-0.4372%)
     
  • 10-Yr Bond

    0.8090
    -0.0320 (-3.80%)
     
  • Vix

    29.29
    +1.74 (+6.32%)
     
  • GBP/USD

    1.2996
    -0.0042 (-0.3223%)
     
  • USD/JPY

    104.9970
    +0.3070 (+0.2932%)
     
  • BTC-USD

    13,188.25
    +111.24 (+0.85%)
     
  • CMC Crypto 200

    263.92
    +0.51 (+0.19%)
     
  • FTSE 100

    5,842.82
    -17.46 (-0.30%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

·2 mins read

Shareholders with $100,000 losses or more are encouraged to contact the firm

Law Offices of Howard G. Smith announces an investigation on behalf of NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) investors concerning the Company’s possible violations of federal securities laws.

On January 13, 2020, NextCure disclosed that Eli Lilly and Company had ended its collaboration agreement for the research and development of the Company’s leading product candidate, NC318, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor particularly for patients with advanced or metastatic solid tumors.

On this news, the Company’s share price fell $4.70, or 8%, to close at $52.00 per share on January 13, 2020, thereby injuring investors.

Then, on July 13, 2020, before the market opened, NextCure announced that it was no longer planning to "advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial." The same day, the Company announced that its Chief Medical Officer resigned.

On this news, the Company’s share price fell $9.73, or 54%, to close at $8.15 per share on July 13, 2020, thereby injuring investors further.

If you purchased NextCure securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200922006043/en/

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com